| イタリア | トルコ | オーストリア | |
| 血漿交換術 | から $2,200 | から $1,200 | から $2,000 |
| 多発性硬化症リハビリテーション | から $4,500 | から $3,000 | から $10,000 |
| 多発性硬化症の薬物療法 | から $5,500 | から $2,500 | から $2,000 |
| オクレリズマブ | から $35,000 | から $10,000 | から $35,000 |
| 血漿交換 | から $2,250 | から $3,900 | - |
Bookimedは多発性硬化症治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。国に到着時にクリニックで治療代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。多発性硬化症治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。多発性硬化症治療の旅路でお一人になることはありません。
Italy hosts leading neurology centers recognized globally for multiple sclerosis (MS) care. Top-rated facilities include San Raffaele Hospital and San Donato Hospital in Milan. These institutions hold IRCCS accreditation for combining clinical excellence with advanced research. They rank among the best specialized hospitals globally.
Bookimed Expert Insight: Data shows Milan is the primary hub for MS care. Hospitals like San Raffaele and San Donato serve over 300,000 patients annually. This high volume ensures specialists manage diverse MS cases regularly. Choosing these larger IRCCS centers often provides faster access to the latest disease-modifying therapies. These treatments may reach smaller regional hospitals much later.
Patient Consensus: Patients note that university hospitals in Milan and Rome offer the best specialist access. Many recommend using private consultations to skip long public wait times for initial diagnosis. Traveling from southern regions to northern centers is common to access newer monoclonal antibody treatments.
The latest Disease-Modifying Therapies (DMTs) for multiple sclerosis are available in Italy. The Italian Pharmaceutical Agency (AIFA) authorizes and reimburses high-efficacy treatments. Patients access these therapies through specialized MS centers. Availability includes S1P receptor modulators and monoclonal antibodies like ocrelizumab.
Bookimed Expert Insight: Data shows a clear advantage in seeking treatment at IRCCS-accredited facilities in Milan. San Raffaele and San Donato Hospital both maintain this research designation. These institutions often provide faster access to newer protocols. They serve over 300,000 patients annually and integrate the latest research directly into clinical practice.
Patient Consensus: Patients note it is important to document all disease activity to speed up drug approvals. Those in Northern Italy often report shorter waiting times for receiving their first infusions.
International patients can obtain remote second opinions from leading Italian neurological centers specializing in Multiple Sclerosis. Institutions like San Raffaele Research Hospital in Milan provide virtual consultations via secure platforms. Specialists review clinical history, laboratory reports, and MRI scans to confirm diagnoses or suggest treatment adjustments.
Bookimed Expert Insight: San Raffaele and San Donato share the same Italian Ministry of Health accreditation. Both facilities manage over 300,000 patients annually using high-volume research protocols. This shared infrastructure ensures that even remote consultations benefit from Europe's largest clinical data pools. Choosing either facility provides access to identical quality standards for complex neuro-immunological reviews.
Patient Consensus: Patients note that uploading high-quality MRI scans in advance is the most critical step. They suggest using translation tools for initial outreach to ensure clinical records are understood correctly.
Italy's National Health Service (SSN) provides free or highly subsidized care for Multiple Sclerosis. Patients access specialized centers for diagnosis and monitoring. Disease-modifying therapies (DMTs) are fully covered. The system includes exemptions for specialist visits and diagnostic tests like MRI scans.
Bookimed Expert Insight: Quality of care often correlates with research hospital status. Facilities like San Raffaele and San Donato in Milan hold IRCCS accreditation. This status combines clinical care with advanced research activities. Data shows these northern centers often provide faster access to innovative treatments. This includes protocols like hematopoietic stem cell transplantation (HSCT) for aggressive cases.
Patient Consensus: Patients value the zero-cost access to expensive medications compared to other countries. Many note it is important to prepare for bureaucratic delays when applying for disability pensions.